ARGOS THERAPEUTICS INC (ARGS) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
4233 TECHNOLOGY DR DURHAM, NC 27704 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 12,126 | 17,016 | 15,189 | 9,373 | 9,337 | 11,138 | |||
| Cash and cash equivalent | 12,126 | 17,016 | 15,189 | 9,373 | 9,337 | 11,138 | |||
| Restricted cash and investments | 740 | 740 | 2,442 | ||||||
| Receivables | 79 | 457 | 143 | 26 | 42 | 137 | |||
| Asset, held-for-sale, not part of disposal group | 600 | 10,337 | 10,342 | 10,342 | |||||
| Other undisclosed current assets | 1,961 | 1,342 | 1,252 | 1,387 | 1,431 | 1,468 | |||
| Total current assets: | 14,166 | 18,816 | 17,184 | 21,862 | 21,892 | 25,526 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 2,611 | 3,338 | 3,582 | 3,861 | 4,055 | 4,305 | |||
| Other noncurrent assets | 11 | 11 | 11 | 11 | 11 | 11 | |||
| Total noncurrent assets: | 2,622 | 3,349 | 3,593 | 3,872 | 4,066 | 4,316 | |||
| TOTAL ASSETS: | 16,788 | 22,164 | 20,778 | 25,734 | 25,958 | 29,842 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,683 | 3,918 | 2,235 | 7,273 | 8,180 | 9,401 | |||
| Accounts payable | 114 | 1,002 | 971 | 823 | 794 | 3,356 | |||
| Accrued liabilities | 2,569 | 2,917 | 1,264 | 6,449 | 7,386 | 6,046 | |||
| Debt | 4,980 | 4,976 | 4,973 | 18 | 18 | 18 | |||
| Restructuring reserve | 150 | 293 | 2,493 | ||||||
| Other undisclosed current liabilities | 1,835 | 2,130 | 2,350 | 2,126 | 5,993 | 5,164 | |||
| Total current liabilities: | 9,498 | 11,025 | 9,557 | 9,567 | 14,484 | 17,075 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 12,134 | 15,755 | 6,580 | 6,498 | |||||
| Long-term debt, excluding current maturities | 12,134 | 15,755 | 6,580 | 6,498 | |||||
| Liabilities, other than long-term debt | 9,886 | 8,738 | 6,471 | 6,404 | 6,762 | 569 | |||
| Contract with customer, liability | 3,299 | 2,276 | ✕ | ✕ | ✕ | ✕ | |||
| Due to related parties | 6,587 | 6,444 | 6,303 | 6,159 | 6,016 | ||||
| Derivative instruments and hedges, liabilities | 19 | 168 | 244 | 746 | 569 | ||||
| Total noncurrent liabilities: | 9,886 | 8,738 | 18,604 | 22,159 | 13,342 | 7,067 | |||
| Total liabilities: | 19,383 | 19,763 | 28,161 | 31,727 | 27,825 | 24,142 | |||
| Equity | |||||||||
| Equity, attributable to parent | (8,136) | (3,179) | (9,234) | (16,974) | (20,573) | (13,771) | |||
| Common stock | 11 | 10 | 6 | 79 | 42 | 41 | |||
| Additional paid in capital | 373,140 | 371,615 | 363,450 | 353,743 | 344,120 | 342,387 | |||
| Accumulated other comprehensive loss | (131) | (129) | (126) | (125) | (130) | (133) | |||
| Accumulated deficit | (381,154) | (374,676) | (372,564) | (370,671) | (364,606) | (356,067) | |||
| Total equity: | (8,136) | (3,179) | (9,234) | (16,974) | (20,573) | (13,771) | |||
| Other undisclosed liabilities and equity | 5,541 | 5,581 | 1,851 | 10,982 | 18,706 | 19,471 | |||
| TOTAL LIABILITIES AND EQUITY: | 16,788 | 22,164 | 20,778 | 25,734 | 25,958 | 29,842 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 54 | 5,933 | 1,671 | 53 | 70 | 105 | ||
| Gross profit: | 54 | 5,933 | 1,671 | 53 | 70 | 105 | ||
| Operating expenses | (6,420) | (8,044) | (4,015) | (8,108) | (8,145) | (44,089) | ||
| Operating loss: | (6,366) | (2,111) | (2,344) | (8,055) | (8,076) | (43,984) | ||
| Nonoperating income (expense) | (113) | (0) | 451 | 1,989 | (463) | 26 | ||
| Investment income, nonoperating | 20 | 18 | 14 | 11 | 9 | 31 | ||
| Other nonoperating income (expense) | 1 | (18) | (22) | 36 | (5) | |||
| Interest and debt expense | (152) | (149) | 600 | 1,507 | (294) | 249 | ||
| Loss from continuing operations: | (6,631) | (2,260) | (1,293) | (4,559) | (8,833) | (43,709) | ||
| Loss before gain (loss) on sale of properties: | (6,631) | (2,260) | (1,293) | (4,559) | (8,833) | (43,709) | ||
| Net loss: | (6,631) | (2,260) | (1,293) | (4,559) | (8,833) | (43,709) | ||
| Other undisclosed net income (loss) attributable to parent | 152 | 149 | (600) | (1,507) | 294 | 19,629 | ||
| Net loss available to common stockholders, diluted: | (6,479) | (2,111) | (1,893) | (6,066) | (8,539) | (24,080) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (6,631) | (2,260) | (1,293) | (4,559) | (8,833) | (43,709) | ||
| Other undisclosed comprehensive income (loss) | 149 | 146 | (601) | (1,502) | 297 | 19,630 | ||
| Comprehensive loss, net of tax, attributable to parent: | (6,481) | (2,114) | (1,894) | (6,061) | (8,536) | (24,079) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.